Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations

Oncogene

Volumn 30, Issue 47, 2011, Pages 4757-4764

  Rowh, M A W ^a,b,c   Demicco, A ^a,b,c   Horowitz, J E ^a,b,c   Yin, B ^a,b,c   Yang Iott, K S ^b,c   Fusello, A M ^b,c   Hobeika, E ^d   Reth, M ^d   Bassing, C H ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

B lineage lymphomas; Igh c myc translocations; P53

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; MUTANT PROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROTECTION; CELL TRANSFORMATION; CLONAL VARIATION; DOUBLE STRANDED DNA BREAK; EMBRYO DEVELOPMENT; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOMIC INSTABILITY; GERM LINE; IMMUNOGLOBULIN GENE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTE TRANSFORMATION; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; RECEPTOR GENE; SOMATIC MUTATION; TP53 GENE; WILD TYPE;

ANIMALS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL LINEAGE; DNA BREAKS, DOUBLE-STRANDED; DNA END-JOINING REPAIR; FEMALE; GENES, IMMUNOGLOBULIN; GENES, MYC; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, B-CELL; MALE; MICE; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 81855194005     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.191     Document Type: Article

References (39)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
2. Bassing CH, Ranganath S, Murphy M, Savic V, Gleason M, Alt FW. (2007). Aberrant V(D)J recombination is not required for rapid development of H2ax/p53 deficient thymic lymphomas with clonal translocations. Blood 111: 2163-2169.
3. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M et al. (2003). Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114: 359-370.
4. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA et al. (2003a). H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114: 371-383.
5. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, Lee A et al. (2003b). Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5: 675-679.
6. Cheung AMY, Hande MP, Jalali F, Tsao M-S, Skinnider B, Hirao A et al. (2002). Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Res 62: 6194-6204.
7. Cheung KJ, Horsman DE, Gascoyne RD. (2009). The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 146: 257-269.
8. Difilippantonio MJ, Petersen S, Chen HT, Johnson R, Jasin M, Kanaar R et al. (2002). Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med 196: 469-480.
9. Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE et al. (2000). DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 404: 510-514.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
11. Dujka ME, Puebla-Osorio N, Tavana O, Sang M, Zhu C. (2010).ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo. Oncogene 29: 957-965.
12. Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A et al. (2010). Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29: 4007-4017.
13. Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM et al. (2000). Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404: 897-900.
14. Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ et al. (1998). A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 95: 891-902.
15. Giblin W, Chatterji M, Westfield G, Masud T, Theisen B, Cheng H-L et al. (2009). Leaky severe combined immunodeficiency and aberrant DNA rearrangements due to a hypomorphic RAG1 mutation. Blood 113: 2965-2975.
16. Gladdy RA, Taylor MD, Williams CJ, Grandal I, Karaskova J, Squire JA et al. (2003). The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell 3: 37-50.
17. Haines BB, Ryu CJ, Chang S, Protopopov A, Luch A, Kang YH et al. (2006). Block of T cell development in P53-deficient mice accelerates development of lymphomas with characteristic RAG-dependent cytogenetic alterations. Cancer Cell 9: 109-120.
18. Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R et al. (2006). Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci USA 103: 13789-13794.
19. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
20. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425.
21. Kuppers R. (2005). Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5: 251-262.
22. Liao MJ, Zhang XX, Hill R, Gao J, Qumsiyeh MB, Nichols W et al. (1998). No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol Cell Biol 18: 3495-3501.
23. Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, Kanaar R et al. (2001). Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci USA 98: 9209-9214.
24. MacPherson D, Kim J, Kim T, Rhee BK, van Oostrom CThM, DiTullio Jr RA et al. (2004). Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 23: 3689-3699.
25. Nepal RM, Zaheen A, Basit W, Li L, Berger SA, Martin A. (2008).AID and RAG1 do not contribute to lymphomagenesis in Emu cmyc transgenic mice. Oncogene 27: 4752-4756.
26. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM et al. (2006). Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440: 105-109.
27. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. (2007). p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189.
28. Robbiani DF, Bunting S, Feldhahn N, Bothmer A, Camps J, Deroubaix S et al. (2009). AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell 36: 631-641.
29. Rooney S, Sekiguchi J, Whitlow S, Eckersdorff M, Manis JP, Lee C et al. (2004). Artemis and p53 cooperate to suppress oncogenic Nmyc amplification in progenitor B cells. Proc Natl Acad Sci USA 101: 2410-2415.
30. Santos MA, Huen MS, Jankovic M, Chen HT, Lopez-Contreras AJ, Klein IA et al. (2010). Class switching and meiotic defects in mice lacking the E3 ubiquitin ligase RNF8. J Exp Med 207: 973-981.
31. Silver DP, Livingston DM. (2001). Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol Cell 8: 233-243.
32. Slatter TL, Ganesan P, Holzhauer C, Mehta R, Rubio C, Williams G et al. (2009). p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Diff 17: 540-550.
33. Smith DP, Bath ML, Harris AW, Cory S. (2005). T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC. Oncogene 24: 3544-3553.
34. Vousden KH, Prives C. (2009). Blinded by the Light: The growing complexity of p53. Cell 137: 413-431.
35. Wang JH, Alt FW, Gostissa M, Datta A, Murphy M, Alimzhanov MB et al. (2008). Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med 205: 3079-3090.
36. Wang JH, Gostissa M, Yan CT, Goff P, Hickernell T, Hansen E et al. (2009). Mechanisms promoting translocations in editing and switching peripheral B cells. Nature 460: 231-236.
37. Wu C, Bassing C.H, Jung D, Woodman BB, Foy D, Alt FW. (2003). Dramatically increased rearrangement and peripheral representation of Vbeta14 driven by the 30Dbeta1 recombination signal sequence. Immunity 18: 75-85.
38. Yin B, Yang-Iott KS, Chao L, Bassing CH. (2010). Cellular context dependent effects of H2ax and p53 deletion upon the development of thymic lymphoma. Blood Oct 117: 175-185. [Epub ahead of print].
39. Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J et al. (2002). Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109: 811-821.